Immunomedics Inc., a biopharmaceutical company based in Morris Plains, announced on Monday its board of directors has appointed Harout Semerjian as CEO and president, and member of the board, effective April 16.
“I am delighted that Harout has agreed to join us at this critical juncture in the evolution of Immunomedics. He is a seasoned global pharmaceutical leader with a passion for and expertise in oncology. His long and successful track record in leading cross functional teams and delivering on ambitious results will be instrumental in scaling the Company and its global operations for the next phase of growth as we are transitioning into a fully-integrated biopharmaceutical company,” Dr. Behzad Aghazadeh, executive chairman of the board, said.
Semerjian, a pharmaceutical veteran with 25 years of life science experience, most recently served as the executive vice president and chief commercial officer at Ipsen. Before that, he spent 16 years at Novartis Oncology in a variety of strategy and operational roles, most recently as senior vice president, global head for Ribociclib.
The company also said Scott Canute will step down from his role as executive director and resume his role as a board member.
“The board and I are extremely grateful to Scott for the leadership he provided over the course of the last year to enable the resubmission of our biologics license application. Scott’s tireless commitment throughout the complete response letter remediation process were instrumental in bringing us to where we are today,” Aghazadeh said.